All Articles

Incretin-based therapy for MASH: are two better than one?

Pharmacologic management of metabolic and alcohol-associated liver disease

Advanced glycation endproduct-RAGE signaling fosters diabetic cardiomyopathy by enhancing cuproptosis and mitochondrial injury

Mechanism-driven therapy for diabetic cardiovascular disease

Podocyte lipotoxicity in diabetic kidney disease: mechanisms and targets

Wilson disease revisited: is the gut a metabolically vulnerable target organ?

Navigating gut-liver metabolic homeostasis: the role of the autonomic nervous system

Sex and age genetic overlap between body mass index and attention deficit hyperactivity disorder in twins

Variation spectrum and reevaluation of selected VUS of ATP7B in a Chinese Wilson disease cohort

Thrombospondin 1 is associated with MASH and hepatic macrophage inflammatory responses via CD47

Genetic predisposition to diabetes mellitus causally increases acute pancreatitis risk

The impact of phthalate exposure on cardiometabolic risk progression in children and the modifying role of movement behaviors

Application and interpretation of non-invasive testing in MetALD

Alterations in the serum lipid profile predict incident diabetes in obese individuals

High glucose induces hypoxanthine accumulation, linking hyperglycemia to adipocyte dysfunction

Metabolic biomarkers predict subclinical cardiac remodeling in obese individuals

Reconsidering metabolic adaptation in weight loss evidence: insights and potential limitations of tirzepatide-induced fat oxidation

Semaglutide in MASH with F2-F3 fibrosis: a holistic perspective on the ESSENCE phase 3 trial